Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Davis Polk Advises Notre Dame Intermédica on Its R$2.7 Billion Equity Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the…
Atreca $125 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public…
Personalis, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $155 million…
Stoke Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of…
Orchard Therapeutics plc Approximately $128 Million Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the…
IDEAYA Biosciences, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of…
NeoGenomics Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering…
Bristol-Myers Squibb Company $19 Billion Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $19 billion…
Intercept Pharmaceuticals, Inc. Concurrent $231 Million Common Stock Offering and $230 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760…